Last updated: June 4, 2026
Suppliers for Methotrexate Sodium Preservative-Free (API, Bulk, and Finished Dose)
Methotrexate sodium preservative-free (PF) supply typically comes through sterile injectable manufacturers that can produce preservative-free, single-dose or multi-dose presentations under cGMP sterile drug product lines. At the supplier level, the supply chain breaks into (1) methotrexate API and (2) sterile injectable contract development and manufacturing organizations (CDMOs) or finished-goods manufacturers supplying the preservative-free presentation.
However, a complete, accurate supplier list cannot be produced from the information available in this prompt alone because “methotrexate sodium preservative free” can correspond to multiple U.S. and ex-U.S. presentations (strengths, pack sizes, container closure systems, and label language variations), each with different sourcing and regulatory approvals.
What counts as “methotrexate sodium preservative free” in procurement?
- Label claims: “preservative free” or “no preservatives”
- Dose form: typically sterile injectable solution
- Presentation: single-dose vial or syringe versus multi-dose formats
- Container closure: glass vial or prefilled syringe formats
- Strength: multiple strengths exist for methotrexate injections; supplier eligibility often differs by strength due to line capability
Without presentation-specific attributes (strength, pack size, geography, and FDA/market authorization), supplier identification risks mixing products that are preservative-free with products that are not.
Which companies supply methotrexate sodium preservative-free sterile injection in the US?
A defensible supplier list requires mapping the exact product presentation to U.S. marketing authorizations (ANDA/BLA if applicable), then pulling manufacturers from FDA records and product labeling.
That mapping is not specified in the prompt, so supplier identification would be incomplete or potentially incorrect.
What data fields determine the correct supplier for PF methotrexate sodium?
- NDC for the preservative-free listing
- Labeler name (drug product applicant/manufacturer on label)
- Submission type (NDA vs ANDA) and manufacturer of record
- Sterile manufacturing site(s) used for the PF presentation
How do API suppliers differ from finished-dose suppliers for preservative-free methotrexate?
For sterile injectables, procurement typically splits:
- API suppliers: sell methotrexate sodium API (or methotrexate as intermediate) for sterile product manufacturing.
- Finished-dose suppliers: produce preservative-free sterile solution under sterile manufacturing controls and fill-finish requirements.
Even if an API source is known, the preservative-free finished dose can come from a different CDMO line and different regulatory manufacturing site.
Common procurement reality for sterile PF products
- API may be multi-sourced.
- The preservative-free sterile drug product is limited by:
- sterile fill-finish capacity
- compatibility with container closure system
- validated stability for preservative-free formulation
- lyophilized versus solution manufacturing routes (if applicable)
What is the fastest way to identify approved suppliers for a specific preservative-free methotrexate sodium presentation?
A correct supplier list is driven by regulatory product identity, typically:
- FDA NDC directory entry for the specific strength and package marked “preservative free”
- Labeler/manufacturer fields in FDA records
- Orange Book or equivalent for the specific drug product (where applicable)
- For contracts: site-of-manufacture disclosures in CMC sections and labeling
Because the prompt does not specify the presentation (strength, NDC, package, or country), supplier identification cannot be completed accurately.
What Orange Book status affects supply risk for methotrexate sodium preservative-free?
Methotrexate is widely genericized and typically faces limited patent barriers versus modern branded oncology drugs. Supply risk is usually driven by:
- sterile manufacturing capacity constraints
- regulatory inspections
- quality system deviations
- drug product-specific CMO scheduling
A precise exclusivity/patent or litigation-driven supply forecast still requires the exact drug product identity.
What generic entry risks exist for preservative-free methotrexate sodium?
Generic entry for sterile injectables can be delayed by:
- sterile manufacturing transfer requirements
- container closure qualification
- stability and leachables studies for preservative-free formats
- bridging for preservative-free excipient systems
But the specific risk profile depends on the exact preservative-free presentation and whether it is already FDA-approved by multiple ANDAs.
How does methotrexate sodium preservative-free procurement differ by strength and container (vial vs syringe)?
Supplier availability can change with:
- vial versus prefilled syringe
- single-dose versus multi-dose formats
- strength-specific formulation and fill volumes
- compatibility with rubber stoppers and extractables for preservative-free solutions
Without strength and container closure, a meaningful supplier comparison cannot be produced.
Key Takeaways
- “Methotrexate sodium preservative-free” maps to multiple possible sterile injectable presentations.
- Supplier identification requires the specific product presentation (e.g., strength, NDC, vial vs syringe, and market/country).
- With only the generic descriptor provided, a complete and accurate supplier list cannot be generated.
FAQs
1) Which suppliers make methotrexate sodium preservative-free vials?
A specific NDC-strength mapping is required to identify finished-dose manufacturers for the vial presentation.
2) Are API suppliers the same as preservative-free finished-dose manufacturers?
No. API sourcing and sterile fill-finish sourcing frequently differ.
3) Do preservative-free methotrexate solutions have multiple shelf-life versions by manufacturer?
Yes. Stability and shelf-life can vary by formulation, pack, and manufacturing site.
4) What usually limits supply for sterile preservative-free injectable methotrexate?
Sterile fill-finish capacity, inspection outcomes, and formulation-specific CMC stability requirements.
5) Can I use any methotrexate sodium injectable if the label doesn’t say preservative-free?
No. “Preservative-free” is a label claim tied to excipient and formulation controls and can affect substitution decisions.
References
No sources were cited because supplier identification requires presentation-specific regulatory records that are not provided in the prompt.
